Evidence map›Paper›PMID 39745842›Full record

ArticleJournal of managed care & specialty pharmacy2025

Estimating optimal thresholds for adherence to RASA medications among older adults with hypertension.

Megha A Parikh, Sujith Ramachandran, Irene Nsiah, Patrick J Campbell, Melissa Castora-Binkley, Taruja Karmakar, Heather Black, John P Bentley

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A primer on clinical programs in managed care pharmacy.Journal of managed care & specialty pharmacy · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Megha A ParikhPharmacy Quality Alliance, Alexandria, VA.
Sujith RamachandranUniversity of Mississippi School of Pharmacy, University.
Irene NsiahUniversity of Mississippi School of Pharmacy, University.
Patrick J CampbellMerck & Co., Inc., Rahway, NJ.
Melissa Castora-BinkleyPharmacy Quality Alliance, Alexandria, VA.
Taruja KarmakarMerck & Co., Inc., Rahway, NJ.
Heather BlackMerck & Co., Inc., Rahway, NJ.
John P BentleyUniversity of Mississippi School of Pharmacy, University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Centers for Medicare and Medicaid Services (CMS) Star Ratings program incentivizes health plans in Medicare to improve performance on a variety of quality measures such as adherence to renin-angiotensin system antagonists (RASAs). Adherence to RASA medications, defined as having a proportion of days covered (PDC) of at least 80%, has been improving for several years, suggesting that further investigation is needed to assess the appropriateness of the current 80% PDC threshold for medication adherence as an indicator of quality. The 80% PDC threshold has been found to be associated with improved health care resource utilization outcomes; however, little evidence exists to show that this threshold is optimal.

objectiveTo evaluate the association between adherence to RASA medications and health care resource utilization outcomes within a Medicare Advantage population and to identify the optimal PDC threshold that maximizes economic and utilization benefits.

methodsThis retrospective cohort study used de-identified administrative claims data from the 2015 to 2018 in Optum's de-identified Clinformatics Data Mart Database. Inclusion in the study was based on measure specifications for the RASA adherence measure used in the Medicare Part D Star Ratings program. Adherence was assessed over a 1-year period, and health care utilization and medical costs were assessed in the subsequent year. Multivariable logistic regression models were used to assess the relationship between adherence and economic outcomes after accounting for hypothesized confounders.

resultsA total of 1,006,901 individuals were included in the study with an average PDC of 87.5% (SD = 17.8%). During the follow-up period, 12.1% of individuals experienced a hospitalization, 14.81% used an emergency department (ED), and 32.3% visited a non-ED outpatient facility. Each percentage point increase in PDC was significantly associated with decreased odds of hospitalization (odds ratio [OR] = 0.997; 95% CI = 0.997-0.997) and ED visit (OR = 0.997; 95% CI = 0.996-0.997), being in the top decile of payer medical costs (OR = 0.998; 95% CI = 0.997-0.998), and increased odds of outpatient visits (adjusted OR = 1.001; 95% CI = 1.001-1.002). Receiver operator characteristic curve analyses found the optimal PDC thresholds to be 91.5%, 90.7%, 90.7%, and 90.4% for hospitalization (area under the curve [AUC] = 0.527), ED visit (AUC = 0.534), outpatient visit (AUC = 0.501), and medical costs (AUC = 0.532), respectively.

conclusionsThis study demonstrated the importance of medication adherence for preventing undesirable outcomes, such as future hospitalizations, ED visits, and high medical costs, among individuals with hypertension enrolled in Medicare Advantage. The optimal threshold for PDC related to health care resource utilization outcomes was found to be greater than that used in the measure in CMS Star Ratings. Future research should examine the impact of changes in adherence thresholds for economic and clinical outcomes.

Indexed as

Antihypertensive AgentsHypertensionMedication AdherenceAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCohort StudiesFemaleHumansMaleMedicare Part DRetrospective StudiesUnited StatesAngiotensin-Converting Enzyme InhibitorsAntihypertensive Agents

Identifiers

PMID39745842
PMCPMC11695845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.